Tobias Heintges
Overview
Explore the profile of Tobias Heintges including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1483
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hofmann F, Heinemann V, DAnastasi M, Gesenhues A, Hesse N, Fischer von Weikersthal L, et al.
Eur Radiol
. 2022 Aug;
33(2):1174-1184.
PMID: 35976398
Objectives: Early tumor shrinkage (ETS) quantifies the objective response at the first assessment during systemic treatment. In metastatic colorectal cancer (mCRC), ETS gains relevance as an early available surrogate for...
2.
Fischer L, Stintzing S, Fischer von Weikersthal L, Modest D, Decker T, Kiani A, et al.
Br J Cancer
. 2022 May;
127(5):836-843.
PMID: 35637412
Background: The evidence on the efficacy of anticancer therapy is limited in older patients with metastatic colorectal cancer (mCRC). This retrospective analysis of phase III FIRE-3 trial assesses the efficacy...
3.
Stahler A, Stintzing S, von Einem J, Westphalen Benedikt C, Heinrich K, Kramer N, et al.
Eur J Cancer
. 2022 May;
169:223-225.
PMID: 35570084
No abstract available.
4.
Liu L, Erickson N, Ricard I, Fischer von Weikersthal L, Lerch M, Decker T, et al.
Int J Cancer
. 2021 Aug;
150(1):112-123.
PMID: 34431518
Body weight loss is frequently regarded as negatively related to outcomes in patients with malignancies. This retrospective analysis of the FIRE-3 study evaluated the evolution of body weight in patients...
5.
Heinemann V, Fischer von Weikersthal L, Decker T, Kiani A, Kaiser F, Al-Batran S, et al.
Br J Cancer
. 2020 Nov;
124(3):587-594.
PMID: 33154570
Background: Cetuximab plus FOLFIRI improved overall survival compared with bevacizumab plus FOLFIRI in KRAS wild-type metastatic colorectal cancer (mCRC) in FIRE-3, but no corresponding benefit was found for progression-free survival....
6.
Stahler A, Stintzing S, von Einem J, Westphalen C, Heinrich K, Kramer N, et al.
Eur J Cancer
. 2020 Aug;
137:250-259.
PMID: 32810748
Background: Molecular biomarkers and primary tumour sidedness guide treatment decisions in metastatic colorectal cancer. Comprehensive molecular profiling aims to identify targetable alterations and measure tumour mutational burden (TMB) to enable...
7.
Modest D, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, et al.
Oncotarget
. 2017 Dec;
8(62):105749-105760.
PMID: 29285289
Purpose: To assess the impact of primary tumor sidedness on outcome of patients with metastatic colorectal cancer (mCRC) across treatment lines. Patients And Methods: Patients of the FIRE-3 trial (initial...
8.
Holch J, Ricard I, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, et al.
Int J Cancer
. 2017 Oct;
142(5):1047-1055.
PMID: 29047142
In metastatic colorectal cancer (mCRC), liver-limited disease (LLD) is associated with a higher chance of metastectomy leading to long-term survival. However, limited data describes the prognostic and predictive relevance of...
9.
Modest D, Stintzing S, Fischer von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, et al.
Int J Cancer
. 2016 Dec;
140(8):1918-1925.
PMID: 28032641
We explored the association of early tumor shrinkage (ETS) and non-ETS with efficacy of first-line and consecutive second-line treatment in patients with KRAS wild-type metastatic colorectal cancer treated in FIRE-3....
10.
Stintzing S, Modest D, Rossius L, Lerch M, Fischer von Weikersthal L, Decker T, et al.
Lancet Oncol
. 2016 Aug;
17(10):1426-1434.
PMID: 27575024
Background: FIRE-3 compared first-line 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) plus cetuximab with FOLFIRI plus bevacizumab in patients with KRAS exon 2 wild-type metastatic colorectal cancer. The same study also reported...